Efficacy of Narrow Band Spectrum Endoscopy for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis

Overview

the study aims to evaluate the role of similar technology of Narrow Band Imaging VIST video intelligent staining technology in the diagnosis of Gastric Antral Vascular ectasia in cirrhotic patients

Full Title of Study: “Efficacy of Narrow Band Spectrum Endoscopy Versus Histopathology for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 1, 2020

Detailed Description

VIST (Video intelligent staining technology) is used to the diagnosis of GAVE as the form of ectatic vessels in the antrum in instead of erosions in the antrum by White light endoscopy which can mislead the diagnosis to Portal hypertension gastropathy. Targeted biopsies are taken and examined histopathologically in order to see if matching with VIST view. In addition, CD61 is used to highlight the diagnosis for more confirmation. CD61 is an immunohistochemistry platelets marker.

Interventions

  • Diagnostic Test: Upper gastrointestinal endoscopy and biopsy
    • Gastroscope with technology of VIST video intelligent staining technology for taking biopsies

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy of Narrow Band Spectrum endoscopy for the diagnosis of Gastric antral vascular ectasia in cirrhotic patients
    • Time Frame: it is estimated to be 12 months
    • It is done by the new technology of VIST which is similar to Narrow Band Imaging in the diagnosis of Gastric antral vascular ectasia in cirrhotic patients that were misdiagnosed before as portal hypertension gastropathy

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with mucosal vascular lesions at the gastric antrum suspicious of GAVE of a linear striped form or a diffuse punctate form upon conventional WLE Exclusion Criteria:
  • Connective tissue disorders like systemic sclerosis. – Chronic kidney disease. – Recent use of proton pump inhibitors in the last 14 days. – History of gastric surgery or gastric cancer. – Pernicious anemia. – Recent history of non-steroidal anti-inflammatory drugs intake
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Alexandria University
    • Provider of Information About this Clinical Study
      • Principal Investigator: Randa Salah, Assistant lecturer, Internal Medicine Department – Alexandria University
    • Overall Official(s)
      • Randa Salah Eldin Abdelmoneim, Master, Principal Investigator, Alexandria University
    • Overall Contact(s)
      • Amr Abd Elmoety, PhD, 00201111168555, amrmoety@hotmail.com

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.